Flu Seasonal/SARS-CoV-2 mRNA combination vaccine (GlaxoSmithKline)

N/A

Report date: 2026/05/12 15:11:28

Base Information

Drug NameFlu Seasonal/SARS-CoV-2 mRNA combination vaccine (GlaxoSmithKline)

Drug Alias NameSeasonal influenza-SARS COV 2 combined vaccineFlu/COVID-19 mRNA vaccineInfluenza/COVID-19 mRNA vaccinemRNA Flu/COVID-19GSK-5475152

ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccineVaccines > Vaccine type > Combination vaccineVaccines > Application > Prophylactic vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Plc

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A